Prostacyclins in PAH: A Case-Based Treatment Journey

Recorded: March 24, 2026

Pulmonary arterial hypertension (PAH) requires ongoing risk assessment and timely treatment escalation to prevent disease progression and preserve right ventricular function. Despite advances in therapy, clinicians often face uncertainty about when and how to introduce prostacyclin therapies across the treatment spectrum. In this webinar, speakers present a case-based patient journey following a patient with PAH through diagnosis, risk reassessment, and treatment escalation, illustrating how guideline-directed pathways and risk tools can inform clinical decisions. Speakers will explore practical considerations for selecting among oral, inhaled, and parenteral prostacyclin therapies and attendees will learn strategies for optimizing patient-centered care in PAH management.

This activity is sponsored by United Therapeutics.

Continue learning: Access a microlearning activity on inhaled treprostinil delivery options for PAH »